Title: Effect of Progesterone Supplementation to Prevent Preterm Labor
Authors: Dr Cicily T J*, Dr. Sherin Sams, Dr Jincy Job
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.68
Abstract
Preterm birth is the most important problem in maternal and child health throughout the world. It complicates one in eight deliveries and accounts for over 85% of all perinatal morbidity and mortality. On February 3, 2011, the US food and drug administration (FDA) approved the use of progesterone supplementation during pregnancy to reduce the risk of recurrent preterm birth in women without prior spontaneous preterm delivery.
Aim
1. To determine the impact of progesterone therapy in prevention of preterm labor.
2. To measure the maternal and perinatal outcome in those treated by progesterone.
Materials and Methods
Study Design: Randomized control trial
Study Setting: Department of Obstetrics and Gynaecology, Government medical College, Kottayam, Kerala, India
Study Period: March 2012 to March 2014
Methodology: 88 antenatal women with a previous history of spontaneous preterm vaginal delivery were chosen for the study and they were randomly assigned as cases who received progesterone and controls who do not receive progesterone. Natural micronized progesterone is used in this study. There is functional progesterone withdrawal which is a cause for onset and establishment of labor in both preterm and term deliveries. This is the rationale for providing progesterone to prevent preterm labor.
Results: Progesterone is effective in preventing preterm labor in those women with a history of spontaneous preterm labor.
Conclusion: Progesterone supplementation is a very good method to prevent preterm labor and should be continued until 37 weeks. There is significant improvement in neonatal outcome in progesterone users.
Keywords: Vaginal progesterone, Preterm labor, Perinatal outcome.
References
1. Norwitz, Errol R, Lockwood, Charles J and Barrs, Vanessa A. UpToDate. Wolters Kluwer. [Online] 2011. http://cursoen-arm.net/UPTODATE/contents/mobipreview.htm?17/23/17776?source=HISTORY.
2. Progesterone Supplementation to Prevent Preterm Birth. Norwitz, Errol R and Caughey, Aaron B. 2, s.l. : REVIEWS IN OBSTETRICS & GYNECOLOGY, 2011, Vol. 4.
3. Ross, Michael G. Medscape. [Online] 2011. http://emedicine.meds-cape.com/article/260998-overview.
4. Epidemiology and causes of preterm birth. Goldenberg, Robert L , et al., et al. 9606, s.l. : Lancet, 2008, Vol. 371.
5. Cunningham, F Gary , et al., et al.Williams Obstetrics: 23rd Edition. s.l. : Mcgraw-hill, 2009. ISBN: 0071497013, 9780071497015.
6. Maternal Risk Factors and Neonatal Outcome of the. Jahromi, B Namavar , Salarian, L and Shiravani, Z .s.l. : Iranian Red Crescent Medical Journal, 2011, Vol. 13.
7. Desai, Shyam V and Tank, Parikshit .Handbook on Preterm Prelabor Rupture of Membranes in a Low Resource Setting. New Delhi : Jaypee Brothers Medical Publishers ltd., 2012. p. 16. ISBN 978-93-5025-580-3.
8. The health science. [Online] https://thehea-lthscience.com/topics/preterm-labor.
9. Creasy, Robert K, et al., et al.Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice. s.l. : Elsevier Health Sciences, 2013. ISBN 978-1-4557-1137-6.
10. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. O'Brian, J M, et al., et al. 5, s.l. : Ultrasound in Obstetrics and Gynecology, 2007, Vol. 30.
11. Progesterone and Preterm Labor — Still No Definite Answers. Thornton, Jim G. s.l. : The New England Journal of Medicine, 2007.
12. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Glover, M M, et al., et al. 5, s.l. : American Journal of Perinatology, 2011, Vol. 28.
13. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. Caritis, S N, et al., et al. 1, s.l. : American Journal of Obstetrics and Gynecology, 2011, Vol. 205.
14. Transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate. Hemauer, S J, et al., et al. 2, s.l. : American Journal of Obstetrics and Gynecology, 2008, Vol. 199.
15. 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Berghella, Vincenzo, et al., et al. 4, s.l. : American Journal of Obstetrics and Gynecology, 2010, Vol. 202.